Dr. med. Wolf Rösler

Department of Medicine 5 – Haematology and Oncology

Expansion of Plasmablasts at Day 90 after Allogeneic Stem Cell Transplantation Predict Chronic Gvhd (2022) Habenicht KM, Bootz A, Schäfer S, Vasova I, Fante M, Schneider A, Rehli M, et al. Conference contribution CD19-Targeted CAR-T Cells in Refractory Systemic Lupus Erythematosus: Safety, Efficacy, and Mechanistic Insights from the First Five Patients (2022) Müller F, Völkl S, Mougiakakos D, Böltz S, Aigner M, Gary R, Kretschmann S, et al. Conference contribution Reconstitution of EBV-directed T cell immunity by adoptive transfer of peptide-stimulated T cells in a patient after allogeneic stem cell transplantation for AITL (2022) Cobo MFL, Ritter J, Gary R, Seitz V, Mautner J, Aigner M, Völkl S, et al. Journal article Long-Term Results of Allogeneic Stem Cell Transplantation in Adult Ph- Negative High-Risk Acute Lymphoblastic Leukemia (2022) Beelen DW, Arnold R, Stelljes M, Alakel N, Brecht A, Bug G, Bunjes D, et al. Journal article Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus (2022) Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, Völkl S, et al. Journal article Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia (2022) Baron F, Labopin M, Tischer J, Ciceri F, Raiola AM, Blaise D, Sica S, et al. Journal article Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification. (2022) Etra A, Gergoudis S, Morales G, Spyrou N, Shah J, Kowalyk S, Ayuk F, et al. Journal article Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease: M. G. Zewde et al (2021) Zewde MG, Morales G, Gandhi I, Özbek U, Aguayo-Hiraldo P, Ayuk F, Baez J, et al. Journal article Prognostic Value of Elafin in Acute Graft-Versus-Host Disease (2021) Zewde MG, Morales G, Gandhi I, Ozbek U, Aguayo-Hiraldo P, Ayuk FA, Baez J, et al. Conference contribution Allogeneic Hematopoietic Cell Transplantation in Patients <= 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial- (2021) Bornhaeuser M, Schliemann C, Schetelig J, Rollig C, Kramer M, Glass B, Platzbecker U, et al. Conference contribution